Brief: Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur

Sensorion SA

15/02/2021 18:13

Feb 15 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION ANNOUNCES THIRD GENE THERAPY COLLABORATION WITH
INSTITUT PASTEUR TARGETING IMPORTANT PEDIATRIC AND ADULT
DEAFNESS SEGMENTS
    * THREE INITIAL INDICATIONS TO BE TARGETED: CONGENITAL
DEAFNESS, A
PROGRESSIVE FORM OF HEARING LOSS IN CHILDHOOD AND EARLY ONSET OF
SEVERE PRESBYCUSIS IN ADULTS
    * KEY NEW FINDINGS BY INSTITUT PASTEUR CONCERNING GENE
TARGET
GJB2, ENABLES SENSORION TO POTENTIALLY ADDRESS IMPORTANT HEARING
LOSS SEGMENTS IN ADULTS AND CHILDREN

Source text for Eikon:  ID:nNDLJFjK2 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))